Merck’s cancer R&D juggernaut ties up to little Dragonfly’s natural born killer platform — with billions on the line
A little more than a year after Celgene bellied up to the partnership table with $33 million in cash to ally itself with the upstart crew at Dragonfly, Merck has now followed behind in search of what they’re hoping is a game-changing approach to treating solid tumors.
“There’s no company that knows solid tumors more than Merck,” says Dragonfly CEO Bill Haney, who recently jumped into biotech with a pair of new companies looking to make their mark in different fields.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.